Purper-Ouakil D
Service de psychopathologie de l'enfant et de l'adolescent, hôpital Robert-Debré, 48, boulevard Sérurier, 75019 Paris, France.
Arch Pediatr. 2008 Dec;15(12):1834-6. doi: 10.1016/j.arcped.2008.09.026. Epub 2008 Nov 7.
The need for specific psychopharmacology trials in the pediatric population has been recognized and promoted by clinicians and regulatory instances. There are indeed specificities in symptom expression and pharmacological characteristics in this population, and recent studies showed that extrapolation from adult data is not always possible. Available results are insufficient to provide effective guidance for prescription and long-term evaluation of risk/benefit ratio in most indications. The aim of this article is to give an overview of efficacy and safety data in pediatric psychopharmacology.
临床医生和监管机构已经认识到并推动了在儿科人群中开展特定精神药理学试验的必要性。该人群在症状表现和药理学特征方面确实存在特殊性,最近的研究表明,从成人数据进行推断并非总是可行的。现有结果不足以在大多数适应症中为处方及风险/效益比的长期评估提供有效指导。本文旨在概述儿科精神药理学中的疗效和安全性数据。